Successful treatment for diffuse large B-cell lymphoma in a Japanese adolescent with PIK3CD germ-line mutation: stem cell transplantation after reduced-intensity conditioning.

作者信息

Yagasaki Hiroshi, Hirai Maiko, Kanezawa Koji, Ueno Masaru, Hao Hiroyuki, Masuda Shinobu, Sugitani Masahiko, Morioka Ichiro

机构信息

Pediatrics, Nihon University School of Medicine, Tokyo, Japan.

Division of Human Pathology, Department of Pathology, Nihon University School of Medicine, Tokyo, Japan.

出版信息

Ann Hematol. 2022 Jul;101(7):1617-1619. doi: 10.1007/s00277-022-04809-8. Epub 2022 Mar 5.

DOI:10.1007/s00277-022-04809-8

PMID:35247100

Abstract

摘要

相似文献

Successful treatment for diffuse large B-cell lymphoma in a Japanese adolescent with PIK3CD germ-line mutation: stem cell transplantation after reduced-intensity conditioning.

Ann Hematol. 2022 Jul;101(7):1617-1619. doi: 10.1007/s00277-022-04809-8. Epub 2022 Mar 5.

Sequential development of multifocal recurrent non-Hodgkin's lymphoma of mucosa-associated lymphoid tissue and diffuse large B-Cell lymphoma in a single patient: A case report.一例患者黏膜相关淋巴组织多灶性复发性非霍奇金淋巴瘤和弥漫性大B细胞淋巴瘤的序贯发生：病例报告

Medicine (Baltimore). 2018 May;97(21):e10845. doi: 10.1097/MD.0000000000010845.

Successful Curative Therapy With Rituximab and Allogeneic Haematopoietic Stem Cell Transplantation for MALT Lymphoma Associated With STK4-Mutated CD4+ Lymphocytopenia.利妥昔单抗联合异基因造血干细胞移植成功治愈与STK4突变的CD4+淋巴细胞减少相关的黏膜相关淋巴组织淋巴瘤

Pediatr Blood Cancer. 2016 Sep;63(9):1657-9. doi: 10.1002/pbc.26048. Epub 2016 May 10.

High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation Registry.在利妥昔单抗时代弥漫性大 B 细胞淋巴瘤首次复发时采用大剂量化疗和自体干细胞移植：一项基于欧洲血液和骨髓移植登记处数据的分析。

Biol Blood Marrow Transplant. 2012 May;18(5):788-93. doi: 10.1016/j.bbmt.2011.10.010. Epub 2011 Oct 17.

PIK3CD promoted proliferation in diffuse large B cell lymphoma through upregulation of c-myc.PIK3CD通过上调c-myc促进弥漫性大B细胞淋巴瘤的增殖。

Tumour Biol. 2016 Sep;37(9):12767-12777. doi: 10.1007/s13277-016-5225-5. Epub 2016 Jul 22.

R-BEAM versus Reduced-Intensity Conditioning Regimens in Patients Undergoing Allogeneic Stem Cell Transplantation for Relapsed Refractory Diffuse Large B Cell Lymphoma.R-BEAM方案与减低强度预处理方案用于复发难治性弥漫性大B细胞淋巴瘤患者异基因造血干细胞移植的比较

Biol Blood Marrow Transplant. 2020 Apr;26(4):683-690. doi: 10.1016/j.bbmt.2019.10.029. Epub 2019 Nov 1.

Outcomes of rituximab-BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation.利妥昔单抗-BEAM 方案与 BEAM 预处理方案在接受自体移植的弥漫性大 B 细胞淋巴瘤患者中的疗效比较。

Cancer. 2020 May 15;126(10):2279-2287. doi: 10.1002/cncr.32752. Epub 2020 Feb 12.

Comparison of 2 Carmustine-Containing Regimens in the Rituximab Era: Excellent Outcomes Even in Poor-Risk Patients.利妥昔单抗时代两种含卡莫司汀方案的比较：即使在高危患者中也有出色疗效。

Biol Blood Marrow Transplant. 2015 Nov;21(11):1926-31. doi: 10.1016/j.bbmt.2015.06.007. Epub 2015 Jun 16.

Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan plus BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial.用钇-90替伊莫单抗联合BEAM方案进行预处理后自体干细胞移植治疗难治性非霍奇金弥漫性大B细胞淋巴瘤：一项前瞻性、多中心、II期临床试验的结果

Haematologica. 2014 Mar;99(3):505-10. doi: 10.3324/haematol.2013.093450. Epub 2013 Oct 25.

Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial.用钇-90 替伊莫单抗进行预处理后自体干细胞移植治疗难治性非霍奇金弥漫性大 B 细胞淋巴瘤：一项前瞻性、多中心、II 期临床试验结果

Haematologica. 2014 Jul;99(7):e126. doi: 10.3324/haematol.2014.108308.

引用本文的文献

Systematic literature reviews to identify epidemiological, clinical, economic and health-related quality of life evidence in activated PI3Kδ syndrome (APDS).系统性文献综述，以识别活化磷脂酰肌醇-3-激酶δ综合征（APDS）的流行病学、临床、经济和健康相关生活质量证据。

BMC Immunol. 2025 Jul 19;26(1):52. doi: 10.1186/s12865-025-00723-6.

Overall survival among patients with activated phosphoinositide 3-kinase delta syndrome (APDS).活化磷脂酰肌醇3-激酶δ综合征（APDS）患者的总生存期。

Orphanet J Rare Dis. 2025 May 3;20(1):212. doi: 10.1186/s13023-025-03734-z.

Genetic Etiologies and Outcomes in Malignancy and Mortality in Activated Phosphoinositide 3-Kinase Delta Syndrome: A Systematic Review.活化磷脂酰肌醇3-激酶δ综合征的遗传病因与恶性肿瘤及死亡率的结局：一项系统综述

Adv Ther. 2025 Feb;42(2):752-771. doi: 10.1007/s12325-024-03066-7. Epub 2024 Dec 5.

本文引用的文献

Clinical Manifestations and Outcomes of Activated Phosphoinositide 3-Kinase δ Syndrome from the USIDNET Cohort.美国 IDNET 队列中活化的磷酸肌醇 3-激酶 δ 综合征的临床表现和结局。

J Allergy Clin Immunol Pract. 2021 Nov;9(11):4095-4102. doi: 10.1016/j.jaip.2021.07.044. Epub 2021 Aug 2.

Clinical, Immunological, and Genetic Features in Patients with Activated PI3Kδ Syndrome (APDS): a Systematic Review.PI3Kδ 综合征（APDS）患者的临床、免疫学和遗传学特征：系统评价。

Clin Rev Allergy Immunol. 2020 Dec;59(3):323-333. doi: 10.1007/s12016-019-08738-9.

Hematopoietic stem cell transplantation for progressive combined immunodeficiency and lymphoproliferation in patients with activated phosphatidylinositol-3-OH kinase δ syndrome type 1.用造血干细胞移植治疗 1 型活化磷脂酰肌醇-3-羟激酶 δ 综合征患者的进行性联合免疫缺陷和淋巴组织增生。

J Allergy Clin Immunol. 2019 Jan;143(1):266-275. doi: 10.1016/j.jaci.2018.04.032. Epub 2018 May 18.

Disease Evolution and Response to Rapamycin in Activated Phosphoinositide 3-Kinase δ Syndrome: The European Society for Immunodeficiencies-Activated Phosphoinositide 3-Kinase δ Syndrome Registry.激活的磷酸肌醇 3-激酶 δ 综合征中疾病的演变和雷帕霉素的反应：欧洲免疫缺陷学会-激活的磷酸肌醇 3-激酶 δ 综合征登记处。

Front Immunol. 2018 Mar 16;9:543. doi: 10.3389/fimmu.2018.00543. eCollection 2018.

Epstein-Barr Virus Susceptibility in Activated PI3Kδ Syndrome (APDS) Immunodeficiency.活化PI3Kδ综合征（APDS）免疫缺陷中的爱泼斯坦-巴尔病毒易感性。

Front Immunol. 2018 Jan 16;8:2005. doi: 10.3389/fimmu.2017.02005. eCollection 2017.

Effective "activated PI3Kδ syndrome"-targeted therapy with the PI3Kδ inhibitor leniolisib.使用PI3Kδ抑制剂来那度胺进行有效的“活化PI3Kδ综合征”靶向治疗。

Blood. 2017 Nov 23;130(21):2307-2316. doi: 10.1182/blood-2017-08-801191. Epub 2017 Sep 29.

Phosphatidylinositol 3-kinase δ blockade increases genomic instability in B cells.磷脂酰肌醇3激酶δ阻断增加B细胞中的基因组不稳定性。

Nature. 2017 Feb 23;542(7642):489-493. doi: 10.1038/nature21406. Epub 2017 Feb 15.

Hematopoietic stem cell transplant in patients with activated PI3K delta syndrome.伴有活化PI3Kδ综合征患者的造血干细胞移植

J Allergy Clin Immunol. 2017 Mar;139(3):1046-1049. doi: 10.1016/j.jaci.2016.09.040. Epub 2016 Nov 12.

Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome: A large patient cohort study.活化磷脂酰肌醇3-激酶δ综合征的临床谱和特征：一项大型患者队列研究。

J Allergy Clin Immunol. 2017 Feb;139(2):597-606.e4. doi: 10.1016/j.jaci.2016.06.021. Epub 2016 Jul 16.

Identification of variations in the human phosphoinositide 3-kinase p110delta gene in children with primary B-cell immunodeficiency of unknown aetiology.不明病因的原发性B细胞免疫缺陷患儿人类磷酸肌醇3激酶p110δ基因变异的鉴定。

Int J Immunogenet. 2006 Oct;33(5):361-9. doi: 10.1111/j.1744-313X.2006.00627.x.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验